Drucker, Daniel J. http://orcid.org/0000-0001-6688-8127
Article History
Accepted: 7 November 2019
First Online: 17 December 2019
Competing interests
: D.J.D. has served as an adviser or consultant or speaker within the past 12 months to Forkhead Biotherapeutics, Heliome Inc., Intarcia Therapeutics, Kallyope, Merck Research Laboratories, Novo Nordisk Inc., Pfizer Inc. and Sanofi Inc. Neither D.J.D. nor his family members hold stock directly or indirectly in any of these companies. GLP2 is the subject of a patent licence agreement between Shire Inc. and the University of Toronto, Toronto General Hospital (UHN) and D.J.D.